Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 3

Atripla™ – HIV therapy in one pill

Authors Julg B, Bogner JR

Published 6 June 2008 Volume 2008:4(3) Pages 573—577


Boris Julg, Johannes R Bogner

Medizinische Poliklinik, Department of Infectious Diseases, University of Munich Medical School, Downtown Campus, Germany

Abstract: In July 2006 Atripla™ was approved by the US Food and Drug Administration (FDA), combining the active ingredients of one NNRTI and two NRTIs. Atripla™ is the first “one-pill-daily” regimen licensed for the treatment of HIV-1 infection in patients older than 18 years. Atripla™ contains efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg. It therefore combines 3 compounds which have been widely used before and which were recommended for initial therapy due to their potency, tolerability, and safety profile. Efficacy and safety data of efavirenz, tenofovir DF, and emtricitabine are reviewed compared with other antiretroviral drugs, which are used as initial therapy for treatment-naive patient.

Keywords: Atripla™antiretroviral therapy, new “one-pill-daily” regimen, review efficacy and safety data

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

The influence of comorbid personality disorders on recovery from depression

Wongpakaran T, Wongpakaran N, Boonyanaruthee V, Pinyopornpanish M, Intaprasert S

Neuropsychiatric Disease and Treatment 2015, 11:725-732

Published Date: 16 March 2015

Untreated depression in the first trimester of pregnancy leads to postpartum depression: high rates from a natural follow-up study

Yazici E, Kirkan TS, Aslan PA, Aydin N, Yazici AB

Neuropsychiatric Disease and Treatment 2015, 11:405-411

Published Date: 19 February 2015

Insulin resistance and inflammation markers in myocardial infarction

Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O

Journal of Inflammation Research 2013, 6:83-90

Published Date: 17 June 2013

Risk management profile of etoricoxib: an example of personalized medicine

Paola Patrignani, Stefania Tacconelli, Marta L Capone

Therapeutics and Clinical Risk Management 2008, 4:983-997

Published Date: 10 October 2008

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate

Ismail A Mohammed, Alastair J Hutchison

Therapeutics and Clinical Risk Management 2008, 4:887-893

Published Date: 10 October 2008

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Fabio Ferrarese, Gioia Becchimanzi, Massimo Bernardo, Maria Anna Conte, Angela Gioia, et al

Therapeutics and Clinical Risk Management 2008, 4:665-671

Published Date: 8 August 2008

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Therapeutics and Clinical Risk Management 2008, 4:659-663

Published Date: 6 June 2008

A review of nasal polyposis

Jonathan Ray Newton, Kim Wong Ah-See

Therapeutics and Clinical Risk Management 2008, 4:507-512

Published Date: 11 April 2008

Enfuvirtide antiretroviral therapy in HIV-1 infection

Christina MR Kitchen, Miriam Nuño, Scott G Kitchen, Paul Krogstad

Therapeutics and Clinical Risk Management 2008, 4:433-439

Published Date: 11 April 2008